• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Baxano lowers full-year guidance amid widening losses, growing sales

Baxano lowers full-year guidance amid widening losses, growing sales

August 14, 2013 By Arezu Sarvestani

Baxano reinvents itself amid widening losses, growing sales

The newly reinvented Baxano Surgical Inc. (NSDQ:BAXS) failed to meet Wall Street analysts’ expectations during its latest quarter, posting adjusted per-share losses 8¢ deeper than expected. Sales grew 11.4% during the quarter and losses increased 34.9%.

Despite widening losses and a lowered full-year outlook, CEO Ken Reali said he’s "enthusiastic" about the company’s future now that Baxano’s aiming for a new, more promising market.

"This quarter, we created the new Baxano Surgical and now have a suite of spinal devices targeting the minimally invasive spine market, the most significant growth opportunity in spine," Reali said in prepared remarks. "Through the recent transition and integration we have been able to stabilize the business and are enthusiastic about now returning our full focus to driving future revenue growth."

Baxano Surgical was formed after medical device makerTranS1 (NSDQ:TSON) acquired privately held Baxano Inc. in a deal worth about $23.6 million. Reali said at the time that the merger would give the company a strategic foothold in the very alluring segment of the spinal surgery market.

Overall the company posted losses of $8.5 million, or 26¢ per share, on sales of $3.9 million during the 3 months ended June 30. That compared with losses of $6.3 million, or 23¢ per share, on sales of $3.5 million during the same period last year. Adjusted to exclude special charges, quarterly losses came to 21¢ per share, where analysts had predicted losses of 13¢ per share.

Looking forward, Baxano projected Q3 sales in the range of $5.6-$6.2 million. Full-year sales are now expected in the range of $23.5-$25.5 million, compared to the company’s previous estimates in the range of $25-$29 million.

The Raleigh, N.C.-based medical device maker recently found itself having to quell rumors that it was facing harsh layoffs after an anonymous analyst The Spine Blogger claimed that the company had let go of 20% of its workforce due to "inadequate funding and sales" and that the company was "potentially in the initially [sic] stages of a shutdown," as verified by the site’s "sources on the Street."

"We had a small reduction in our workforce, but not a major disruption in the company,"Baxano marketing vice president Amie Borgstrom told MassDevice.com. "[The layoffs] had a lot to do with looking at capital markets and the decline in med-tech venture capital. We said, ‘Let’s position ourselves to be cash-flow positive.’"

BAXS shares were down about 1% in late afternoon trading yesterday, when they were going for $1.91 as of about 2:45 p.m.

Filed Under: MassDevice Earnings Roundup, News Well, Surgical, Wall Street Beat Tagged With: 2013, Baxano Surgical, Q2

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy